?️ Articles on positive diagnosis of NASH/NAFLD; there should be hepatic steatosis by imaging or histology or no significant alcohol consumption.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease, affecting a staggering 30% of the global population.
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases, including non-alcoholic steatohepatitis (NASH).
In this study, a large, global, multidisciplinary panel discussed priorities within the field of fatty liver disease, including its burden, policies surrounding the issue and treatment options.
Research into personalised medicine for non-alcoholic fatty liver disease (NAFLD) underscores the importance of acknowledging NAFLD patients’ unique clinical phenotypes when developing targeted pharmacotherapies.
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are affected by non-alcoholic fatty liver disease (NAFLD).
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
Despite an estimated global prevalence of 38%, no pharmacotherapy has yet been approved for non-alcoholic fatty liver disease (NAFLD).
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.